Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pirbright partners on projects to develop PRRS vaccines
PRRSV is responsible for one of the most damaging diseases to the global pig industry.
Disease costs pig farmers in Europe an estimated €1.5 billion a year. 

The Pirbright Institute has announced that it is joining forces with ECO Animal Health and The Vaccine Group (TVG) in two projects to develop new vaccines for porcine respiratory and reproductive syndrome virus (PRRSC).

PRRSV (type-1 and type -2) is responsible for one of the most damaging diseases to the global pig industry, costing pig farmers in Europe an estimated € 1.5 billion a year and those in the US some $600 million.

The first project will see Pirbirght test two vaccine candidates that use TVG's vaccine technology to assess their effectiveness at tackling PRRSV in pigs. The vaccines are created by using TVG technology to insert non-infectious conserved PRRSV genes supplied by Pirbright into a benign herpesvirus, which then stimulates the immune system when delivered into animals.

Professor Simon Graham, group leader of PRRS Immunology at The Pirbright Institute said, said: “This is an exciting project that takes a novel approach to addressing the urgent requirement for improved vaccines to combat the global spread of PRRSV.”

Associate Professor Dr Michael Jarvis, TVG founder and chief scientific officer,  said: “This is an exciting opportunity that brings together critical basic science and translational expertise towards addressing this major infectious disease in pigs. As PRRSV is a member of the Nidovirus group of viruses, a group that also contains SARS-CoV-2, what we learn from development of a PRRSV vaccine may also help inform our development of a vaccine against SARS-CoV-2.”

In the second project, Pirbright will work with ECO to develop a significantly improved killed vaccine over 18 months. The team will generate modified PRRSV strains and then inactivate them to create vaccine candidates.

Dr Hafid Benchaoui, head of global R&D at the ECO Animal Health Group added: “ECO Animal Health recognises the significant, ongoing challenge that PRRSV poses for pig producers all over the world. This collaboration with The Pirbright Institute and The Vaccine Group leverages the deep scientific expertise of The Pirbright Institute and The Vaccine Group’s novel herpesvirus vector technology in an exciting new approach to PRRSV vaccination.”

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.